Though tiny in size, the pituitary gland functions as the body's central endocrine regulator. As the second most prevalent intracranial neoplasm, most pituitary neuroendocrine tumors (PitNETs) are benign; nevertheless, hormone derangements and mass compression caused by these lesions severely impair patients' quality of life. Early identification and standardized management are therefore of vital importance.

Prior to 2022, PitNETs were universally termed pituitary adenomas. They represent a group of neoplasms arising from anterior pituitary cells with characteristic neuroendocrine differentiation.

PitNETs account for approximately 15% of all intracranial tumors, ranking second only to gliomas in incidence. While the vast majority exhibit benign biological behavior, associated hormonal disturbances and compressive effects on adjacent tissues cannot be overlooked.

01 Rationale Behind the New Nomenclature of Pituitary Tumors

The term “pituitary adenoma” has long been entrenched in clinical practice and patient cognition. However, the 5th WHO Classification of Endocrine Tumors released in 2022 introduced a critical update, formally recommending “pituitary neuroendocrine tumors (PitNETs)” to replace the traditional designation of pituitary adenoma.

This renaming is far more than a cosmetic adjustment; it reflects deeper scientific understanding of the disease's biological nature. The new nomenclature accurately captures their intrinsic neoplastic features and aligns with the naming system applied to neuroendocrine tumors originating from other organs. It eliminates the risk of clinicians and patients underestimating clinical aggressiveness implied by the word “adenoma”.

It should be clarified that despite the inclusion of the word “tumor”, most PitNETs maintain an indolent, benign phenotype. Only a small subset demonstrates invasive properties, and extremely rare cases may metastasize, at which point the diagnosis of pituitary carcinoma is assigned.

02 Pituitary Physiology and Tumorigenesis

Nestled within the sella turcica at the base of the brain, the pituitary gland is pea-sized and weighs merely 0.5 grams. This diminutive organ serves as the master command center of the endocrine system, secreting multiple hormones that govern growth and development, metabolism, reproduction and other core physiological processes.

Connected to the hypothalamus via the pituitary stalk, the gland forms an integrated neuroendocrine regulatory axis. Its blood supply is derived from the hypothalamo-pituitary vasculature, including superior and inferior hypophyseal arteries as well as the hypophyseal portal circulation.

Aberrant proliferation of pituitary parenchymal cells may lead to the formation of PitNETs. The exact etiology remains incompletely elucidated, with current research implicating gene mutations (e.g., G-protein mutations), dysregulated hypothalamic signaling, and local microenvironmental factors surrounding the pituitary gland.

03 Hormonal Disturbances and Mass-Related Manifestations of PitNETs

Clinical presentations of PitNETs fall into two principal categories: symptoms induced by excess hormone secretion, and compressive manifestations arising from mass effect on adjacent structures.

Functional PitNETs overproduce hormones and trigger corresponding clinical syndromes. Prolactinomas constitute the most common functional subtype. Female patients typically present with menstrual irregularities, amenorrhea and galactorrhea, while males frequently suffer from hypogonadism and infertility.

Growth hormone-secreting tumors cause acromegaly in adults, characterized by progressive enlargement of the hands, feet, skull and facial features. In children and adolescents, they result in gigantism. Adrenocorticotropic hormone (ACTH)-producing tumors lead to Cushing syndrome, marked by classic signs including moon facies, buffalo hump, central obesity and cutaneous purple striae.

As lesions expand, they compress surrounding anatomical structures and elicit secondary symptoms. Headache is prevalent, predominantly caused by stretching of the diaphragma sellae or infiltration of parasellar tissues. Compression of the optic chiasm leads to visual deterioration and visual field defects, classically bitemporal hemianopsia.

04 Diagnostic Workup for PitNETs

Diagnosis relies on interdisciplinary collaboration among neurosurgeons, endocrinologists, radiologists and pathologists.

Magnetic resonance imaging (MRI) represents the cornerstone modality for diagnosing and characterizing PitNETs, enabling clear visualization of tumor size, location and anatomical relationships with neighboring tissues. Computed tomography (CT) serves as an alternative for patients ineligible for MRI scanning.

Serum hormonal profiling constitutes another essential diagnostic step. Quantification of growth hormone, prolactin, ACTH and other biomarkers facilitates assessment of tumor secretory activity.

Genetic testing may be indicated for select complex cases, particularly patients with early disease onset or a positive family history of pituitary or endocrine neoplasms. Germline genetic screening is performed to rule out underlying hereditary tumor syndromes.

05 Surgery-Dominant Multimodal Treatment of PitNETs

Treatment regimens are individualized according to tumor subtype, lesion size and secretory status, combining surgical resection, radiotherapy and medical therapy.

Surgical resection is first-line management for nearly all PitNET subtypes excluding prolactinomas. Key therapeutic goals include alleviating compressive symptoms, preserving residual pituitary function, correcting endocrine and metabolic derangements, and obtaining histopathological diagnosis.

Two primary surgical approaches are utilized: transcranial craniotomy and transsphenoidal surgery. Endoscopic transsphenoidal resection has become the gold standard surgical technique. It delivers magnified, direct visualization, facilitates radical tumor removal, achieves robust resolution of endocrine dysfunction, and offers the advantages of minimal tissue trauma, low complication rates and rapid postoperative recovery.

Medical therapy is targeted at specific tumor subtypes. Dopamine agonists are the primary treatment for prolactinomas, while targeted agents such as pasireotide may be administered for ACTH-secreting lesions.

Radiotherapy modalities including fractionated external beam radiation, stereotactic radiosurgery and proton beam therapy are reserved for progressive disease following combined surgical and medical intervention. Adjuvant radiotherapy may be considered 3–6 months postoperatively for residual tumors with elevated proliferative markers or genetic alterations suggestive of invasive behavior.

06 Postoperative Prognosis and Complications of PitNET Surgery

Surgical success rates are determined by tumor size, anatomical location and the patient's overall physical condition.

Microadenomas (<1 cm) generally achieve superior resection outcomes compared with macroadenomas (>1 cm). Literature reports gross total resection rates of 70%–90% for prolactinomas and 60%–80% for growth hormone-secreting adenomas.

Approximately 10%–30% of patients experience tumor recurrence, posing a challenge to long-term surgical efficacy. Regular postoperative surveillance imaging is therefore mandatory.

Potential postoperative complications encompass endocrine insufficiency (deficient secretion of thyroid-stimulating hormone, ACTH and gonadal hormones), cerebrospinal fluid (CSF) leak and visual impairment. The majority of adverse events can be effectively controlled with standardized medical intervention.

Postoperative care requires comprehensive multidisciplinary planning. Monitoring and restoration of endocrine function are critical, entailing serial hormonal testing and hormone replacement therapy when clinically indicated. Early visual rehabilitation training is recommended for patients with persistent visual deficits to improve functional outcomes.

07 Postoperative Lifestyle and Rehabilitation of PitNET Patients

Post-surgical rehabilitation is integral to improving quality of life and lowering recurrence risk. Patients are advised to engage in moderate physical activity as directed by clinicians and maintain balanced dietary and sleep routines to boost physical resilience and recovery capacity.

Regular surveillance is essential for early detection of recurrence and complications. Follow-up frequency is tailored to individual clinical status: monthly monitoring is generally scheduled for the initial six postoperative months, with intervals extended to six months or one year thereafter.

Psychological distress constitutes an often overlooked clinical concern. Diagnosis and treatment of PitNETs impose substantial mental burden on patients. Support can be obtained via psychological counseling and patient support groups. Clinical teams should deliver holistic rehabilitative care to facilitate full physical and psychological recovery.

Patients are encouraged to sustain healthy daily routines: avoid sleep deprivation and overexertion, adhere to a well-balanced diet, and limit consumption of high-fat, high-sugar and high-sodium foods. These lifestyle modifications optimize general physical health and support postoperative recovery.

FAQ

Is pituitary neuroendocrine tumor the same as pituitary adenoma?

Yes, these two terms refer to the identical disease entity at different chronological stages of medical classification. “Pituitary adenoma” is the traditional nomenclature, while the 5th WHO Classification of Endocrine Tumors (2022) updated the official term to pituitary neuroendocrine tumor (PitNETs). The revised name more accurately reflects its neuroendocrine biological profile, standardizes terminology with neuroendocrine tumors arising in other organs, and prevents underestimation of clinical risks associated with the outdated term “adenoma”.

What complications may arise after PitNET surgery?

Postoperative complications include endocrine hypofunction (which may require lifelong hormone replacement therapy), cerebrospinal fluid leak (requiring urgent clinical management), and visual dysfunction (amenable to structured visual rehabilitation). Most complications can be well-managed through consistent surveillance and targeted medical intervention. Regular postoperative follow-up is indispensable for timely identification and treatment of these adverse events.

Although the name pituitary neuroendocrine tumor may sound intimidating, most patients attain excellent long-term outcomes with standardized multidisciplinary care. Advances in medical technology—especially endoscopic neurosurgery and novel targeted pharmacotherapies—have continuously improved patients' quality of life and long-term prognostic outcomes.